دورية أكاديمية
أعرض في EDS

Causal relationship between lipid-lowering drugs and ovarian cancer, cervical cancer: a drug target mendelian randomization study.

التفاصيل البيبلوغرافية
العنوان: Causal relationship between lipid-lowering drugs and ovarian cancer, cervical cancer: a drug target mendelian randomization study.
المؤلفون: Li J; The fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, 518033, China.; Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, 518033, China., Yang Z; Jinan University School of Traditional Chinese Medicine, Guangzhou, Guangdong, 510632, China., Wang T; The fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, 518033, China.; Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, 518033, China., Li M; Department of Nutrition and Food Hygiene, School of Public Health, Wuhan University, Wuhan, 430071, China., Wu X; The fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, 518033, China.; Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, 518033, China., Fu X; The fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, 518033, China.; Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, 518033, China., Yang C; The fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, 518033, China.; Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, 518033, China., Li Y; The fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, 518033, China.; Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, 518033, China., Wang X; The fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, 518033, China.; Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, 518033, China., Lan Z; The fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, 518033, China.; Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, 518033, China., Li M; The fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, 518033, China.; Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, 518033, China., Chen S; The fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, 518033, China. szzyycs@126.com.; Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, 518033, China. szzyycs@126.com.
المصدر: BMC cancer [BMC Cancer] 2024 May 31; Vol. 24 (1), pp. 667. Date of Electronic Publication: 2024 May 31.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2001-
مواضيع طبية MeSH: Uterine Cervical Neoplasms*/genetics , Uterine Cervical Neoplasms*/drug therapy , Mendelian Randomization Analysis* , Hydroxymethylglutaryl CoA Reductases*/genetics , Ovarian Neoplasms*/genetics , Ovarian Neoplasms*/drug therapy , Genome-Wide Association Study* , Proprotein Convertase 9*/genetics, Humans ; Female ; Hypolipidemic Agents/therapeutic use ; Hypolipidemic Agents/adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Polymorphism, Single Nucleotide
مستخلص: Background: The causal impact of lipid-lowering drugs on ovarian cancer (OC) and cervical cancer (CC) has received considerable attention, but its causal relationship is still a subject of debate. Hence, the objective of this study is to evaluate the impact of lipid-lowering medications on the occurrence risk of OC and CC through Mendelian randomization (MR) analysis of drug targets.
Methods: This investigation concentrated on the primary targets of lipid-lowering medications, specifically, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) and proprotein convertase kexin 9 (PCSK9). Genetic variations associated with HMGCR and PCSK9 were derived from published genome-wide association study (GWAS) findings to serve as substitutes for HMGCR and PCSK9 inhibitors. Employing a MR approach, an analysis was conducted to scrutinize the impact of inhibitors targeting HMGCR and PCSK9 on the occurrence of OC and CC. Coronary heart disease (CHD) risk was utilized as a positive control, and the primary outcomes encompassed OC and CC.
Results: The findings of the study suggest a notable elevation in the risk of OC among patients treated with HMGCR inhibitors (OR [95%CI] = 1.815 [1.316, 2.315], p = 0.019). In contrast, no significant correlation was observed between PCSK9 inhibitors and the occurrence of OC. Additionally, the analysis did not reveal any noteworthy connection between HMGCR inhibitors, PCSK9 inhibitors, and CC.
Conclusion: HMGCR inhibitors significantly elevate the risk of OC in patients, but their mechanism needs further investigation, and no influence of PCSK9 inhibitors on OC has been observed. There is no significant relationship between HMGCR inhibitors, PCSK9 inhibitors, and CC.
(© 2024. The Author(s).)
References: Stroke. 2007 Feb;38(2):281-5. (PMID: 17218611)
BMC Cancer. 2022 Oct 6;22(1):1049. (PMID: 36203122)
Elife. 2018 May 30;7:. (PMID: 29846171)
Bioinformatics. 2019 Nov 1;35(22):4851-4853. (PMID: 31233103)
Oncol Rep. 2011 Jan;25(1):41-7. (PMID: 21109955)
Int J Public Health. 2023 Mar 31;68:1605198. (PMID: 37065642)
Cancer Causes Control. 2009 Jul;20(5):609-16. (PMID: 19043788)
Front Endocrinol (Lausanne). 2022 May 25;13:896369. (PMID: 35692403)
Gynecol Oncol. 2014 Aug;134(2):346-55. (PMID: 24880141)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Nature. 2020 Dec;588(7839):693-698. (PMID: 33177715)
Signal Transduct Target Ther. 2020 Jul 29;5(1):137. (PMID: 32728057)
Int J Cancer. 2009 Jun 15;124(12):2938-41. (PMID: 19267407)
BMC Cancer. 2010 Apr 01;10:125. (PMID: 20359358)
Cancer Res. 2008 Jul 1;68(13):5478-86. (PMID: 18593951)
Curr Probl Cancer. 2018 Sep;42(5):457-465. (PMID: 30064936)
Proteomics Clin Appl. 2013 Jun;7(5-6):355-66. (PMID: 23161554)
Cancers (Basel). 2021 Jul 24;13(15):. (PMID: 34359627)
Exp Ther Med. 2017 May;13(5):1993-1999. (PMID: 28565798)
Int J Cancer. 2022 Apr 1;150(7):1156-1165. (PMID: 34751444)
Eur J Pharmacol. 2023 Jun 15;949:175721. (PMID: 37059376)
Int J Cancer. 2021 Apr 5;:. (PMID: 33818764)
Nat Genet. 2013 Nov;45(11):1274-1283. (PMID: 24097068)
Biochim Biophys Acta Rev Cancer. 2021 Aug;1876(1):188581. (PMID: 34144130)
Genes Cancer. 2015 Nov;6(11-12):472-9. (PMID: 26807200)
Nat Genet. 2018 May;50(5):693-698. (PMID: 29686387)
Front Cardiovasc Med. 2021 Oct 15;8:764038. (PMID: 34782856)
Mini Rev Med Chem. 2023;23(1):24-32. (PMID: 34856898)
Cancer Manag Res. 2021 Dec 06;13:9015-9024. (PMID: 34908877)
Genes (Basel). 2024 Jan 21;15(1):. (PMID: 38275613)
Gynecol Oncol. 2014 Jun;133(3):647-55. (PMID: 24736024)
PLoS Med. 2020 Mar 23;17(3):e1003062. (PMID: 32203549)
Arthritis Res Ther. 2023 Aug 14;25(1):148. (PMID: 37580807)
Heart. 2017 Sep;103(18):1400-1407. (PMID: 28596306)
JAMA. 2017 Nov 21;318(19):1925-1926. (PMID: 29164242)
Breast Cancer Res. 2022 Feb 12;24(1):12. (PMID: 35151363)
Mol Carcinog. 2005 Nov;44(3):151-61. (PMID: 16167351)
Int J Biomed Sci. 2009 Dec;5(4):411-20. (PMID: 23675166)
Prz Menopauzalny. 2023 Jun;22(2):93-104. (PMID: 37674925)
BJOG. 2018 Jul;125(8):1001-1008. (PMID: 29412502)
Gynecol Oncol. 2018 Mar;148(3):540-546. (PMID: 29422345)
Int J Gen Med. 2022 Apr 11;15:3903-3914. (PMID: 35431573)
Front Pharmacol. 2023 Apr 19;14:1109580. (PMID: 37153802)
Cancer Epidemiol Biomarkers Prev. 2018 Sep;27(9):995-1010. (PMID: 29941659)
Best Pract Res Clin Obstet Gynaecol. 2017 May;41:3-14. (PMID: 27743768)
Eur J Obstet Gynecol Reprod Biol. 2022 Jan;268:74-81. (PMID: 34875557)
Cancer Epidemiol Biomarkers Prev. 2021 Nov;30(11):2044-2051. (PMID: 34404683)
معلومات مُعتمدة: 20241262 Guangdong Provincial Bureau of Traditional Chinese Medicine Scientific Research Project; JSGG20220226090203006 Shenzhen Science and Technology Plan Project Innovation and Entrepreneurship Special Project
فهرسة مساهمة: Keywords: Cervical cancer; HMGCR; MR; Ovarian cancer; PCSK9
المشرفين على المادة: EC 1.1.1.- (Hydroxymethylglutaryl CoA Reductases)
EC 1.1.1.- (HMGCR protein, human)
EC 3.4.21.- (PCSK9 protein, human)
EC 3.4.21.- (Proprotein Convertase 9)
0 (Hypolipidemic Agents)
0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
تواريخ الأحداث: Date Created: 20240531 Date Completed: 20240601 Latest Revision: 20240603
رمز التحديث: 20240603
مُعرف محوري في PubMed: PMC11143665
DOI: 10.1186/s12885-024-12434-z
PMID: 38822303
قاعدة البيانات: MEDLINE
الوصف
تدمد:1471-2407
DOI:10.1186/s12885-024-12434-z